Core Tip: Jihai is medicine with the U.S. pharmaceutical giant Pfizer, Merck and the U.S. Simcere joint venture since the September 6, Fosun and Ruishi Long Sand Group joint venture in Shanghai , targeting the Chinese market but also has high-tech barriers needed generic drugs. Market participants said that multinational and local companies to cooperate, not only will help to improve the level of domestic generic drug industry, pharmaceutical companies will also promote China's industrial upgrading, and accelerate international.

Since the second half of this year, foreign pharmaceutical companies frequently powerful alliances, joint development of domestic and international trends in the generics market has become increasingly evident.

Jihai is medicine with the U.S. pharmaceutical giant Pfizer, Merck and the U.S. Simcere joint venture since the September 6, Fosun Group in Shanghai and Rui Shilong sand joint venture, targeting the Chinese needed but also has high-tech market barriers to generic drugs.

Market participants said that multinational and local companies to cooperate, not only will help to improve the level of domestic generic drug industry, pharmaceutical companies will also promote China's industrial upgrading, and accelerate international.
Popular generic drugs market

Benefit from China's rapid economic growth and new medical reform, China's fast-growing pharmaceutical market will usher in a decade. According to IMS is expected that China will in 2020 become the world's second largest pharmaceutical market. At the same time, many drug patents expire, pharmaceutical companies is to enter the Chinese market in generic drugs a good time. According to the China Health Insurance Association concerned parties ,2011-2015, worth $ 77 billion will lose patent protection for pharmaceuticals. For example, in 2010, Pfizer's antidepressant Effexor patent expires, the drug had a record $ 3.8 billion in annual sales record; the company's top products - cholesterol-lowering drug Lipitor's patent will expire in November 2011 In 2010, Pfizer $ 67.8 billion in sales, Lipitor sales accounted for $ 10.7 billion. These drugs patent expires will the profitability prospects of European and American pharmaceutical giant, enormous pressure, but many domestic pharmaceutical companies, it means a huge market opportunity.

In this regard, senior vice president Li Xianlin Fosun told reporters that the majority of global patent drugs are all multinational pharmaceutical companies, these drugs are usually expensive. Therefore, Fosun look forward to international cooperation, development of high drug prices more reasonable, seize market opportunities.
Ruishi Long Sand Group has 100 years of specialty pharmaceutical experience, is a leading global technology and scale of API development and customization businesses, small molecules, peptides, histological and other core technologies in different fields of pharmaceutical research and development and production processes in global leadership. According to members of the Group Management Committee Ruishi Long Sand Harry • Butt told reporters, will cooperate with Fosun by small molecule drugs to enter the generics market.

The two sides first phase of the investment amounting to 100 million yuan, the proportion of their contribution to 50%: 50%, the initial research and development of drugs targeted anti-tumor, anti-infective and cardiovascular therapeutic areas. Joint venture aims by 2020 to become China's leading generics company, to market high-end and affordable prices of medicines.

Harry • Butt pointed out that China in the global pharmaceutical market, accounting for less than 2%, with China's pharmaceutical market growth, China will soon become the world's largest pharmaceutical market. At the same time, although China is expected to become the world's largest producer of pharmaceutical, but only a few companies using the latest technology in the production of high-end drugs, the international cooperation has great potential to explore.

U.S. pharmaceutical giant Pfizer and cooperation of the sea is medicine Luo Jiali, vice president of business development, told reporters that a large international pharmaceutical companies through a strategic partner, we can further consolidate the leading edge technology. According to the sea is medicine's "Twelfth Five Year Plan" goal, the company will accelerate from bulk drugs to formulations, the domestic market to international markets from the extension of the brand to the global generics business transformation.
Zhejiang, a manufacturer of bulk drugs, according to the relevant sources of listed companies, the company is also working with pharmaceutical giant Sanofi and other matters to discuss joint plans for cooperation in generic drugs. "In the patent expires, generic who achieved sooner, who profit the higher the level." The source said.
The internationalization of Chinese pharmaceutical companies to test the water

From the current situation, medical model of international cooperation between enterprises is gradually being accepted by the market.

Brokerage researchers believe that the sea is Pfizer Pharmaceutical cooperation with the United States, is expected for this year's performance bonus. According to reports, the sea is medicine in the past has been with the U.S. Eli Lilly and Company (capreomycin and other projects) and Schering-Plough (En La ADM and other projects) have a good cooperation, also announced earlier this year with Lilly Elanco Animal Health Division , Department of Pfizer veterinary health products long-term cooperation agreement. "The current and Pfizer signed a long-term comprehensive cooperation agreement, which means the company to further deepen international cooperation, it will be possible to undertake more international transfer of production orders." The researchers said this.

The innovation capability and brand, marketing and other comprehensive selection of high quality foreign domestic partners is the focus when considering. Fosun years of sustained investment in innovation, imitation created with the establishment of R & D system, the focus of cardiovascular, metabolic, anti-infective, anti-tumor and other key areas, and in these areas with a certain advantage.

According to the Fuxing Group Vice Chairman, Chief Executive Officer Liang Xinjun told reporters, as China's leading pharmaceutical companies, generic drug Fosun will seize the opportunity to enhance their international competitiveness, is committed to the company into an international enterprise.

International is China's leading pharmaceutical development companies. Health Insurance Association data show that the current domestic total of 24 companies in Europe and America certified by the production line, more and more domestic pharmaceutical companies to enter the international arena.

Of course, the international road is not flat. In Luo Jiali view, preparations for the export of domestic enterprises now at only in the establishment of production lines and the new drug application stage, these are just the beginning of the export of agents, should be truly international channels, including overseas expansion, including its own brand maintenance systems engineering. (From Medicine Economic News)